The Evidence Debate: Why the WHO's New Traditional Medicine Strategy is Facing Backlash

For decades, global health policy has operated on a strict binary: modern, evidence-based biomedicine on one side, and traditional or alternative practices on the other. But as the World Health Organization (WHO) rolls out its Global Traditional Medicine Strategy 2025–2034, that dividing line is becoming the center of a fierce scientific and methodological debate.[2][6]

The WHO's decade-long roadmap aims to integrate traditional, complementary, and integrative medicine (TCIM) into national health systems worldwide. The goal is to provide universal access to safe and effective care, acknowledging that ancient healing practices remain the primary source of healthcare for billions of people, particularly in the developing world.[2][3][4]

However, a scathing new critique published in The BMJ argues that the WHO is fundamentally compromising scientific integrity to achieve this integration. Authored by a coalition of physicians and health policy experts, the editorial accuses the WHO of lowering evidentiary standards to accommodate therapies that have not proven their efficacy in rigorous clinical trials.[1][5]

At the heart of the dispute is how the medical community defines "evidence." The gold standard for modern medicine is the randomized controlled trial (RCT), which isolates a specific intervention to measure its exact effect against a placebo. The BMJ critics argue that the WHO strategy bypasses this requirement by endorsing observational studies and "real-world data" as sufficient proof for integrating traditional practices.[1]

"Despite claiming evidence must precede integration, the strategy also allows member states to fund and integrate CAM before standard efficacy and public safety data exist, which is ethically and methodologically indefensible," the authors wrote in The BMJ. They warn that this approach risks legitimizing unproven interventions from the pre-scientific era.[1][5]

The stakes of this methodological shift are immense. The global market for complementary and alternative medicine is projected to reach $359 billion by 2032. Critics warn that without strict RCT requirements, the WHO's endorsement could fuel an "infodemic" of health misinformation and empower commercial interests to exploit vulnerable patients with ineffective or dangerous products.[1][5]

Safety is a primary concern for the critics. The editorial highlights the risk of hepatotoxicity—severe liver damage—caused by unregulated herbal supplements, as well as dangerous interactions between traditional remedies and conventional prescription drugs. The authors argue that a patient's right to choose their healthcare must be grounded in transparent, scientifically validated information about both benefits and harms.[1]

But defenders of the WHO strategy argue that the critique misrepresents the organization's goals and ignores the realities of global public health. According to the WHO, over 80% of the global population across 170 member states uses some form of traditional medicine. In many low- and middle-income countries, it is not a lifestyle choice but the only accessible and affordable care available.[2][3][4]

From the WHO's perspective, the new strategy does not lower standards; rather, it attempts to bring a vast, unregulated sector out of the shadows. By establishing a framework for research, pharmacovigilance, and practitioner training, the WHO aims to protect patients who are already using these therapies daily, while gradually building a more robust evidence base.[2][4]

Furthermore, public health pragmatists argue that complex, holistic medical systems—such as Ayurveda, Traditional Chinese Medicine, or Indigenous healing practices—cannot always be accurately evaluated using reductionist RCTs. These systems often rely on highly individualized, multi-component treatments that change over time, making standard placebo-controlled trials logistically and ethically challenging.[3][6]

In rapid responses published in The BMJ, several researchers pointed out that real-world data and observational studies are increasingly recognized as valid tools in modern evidence-based medicine. They argue that acknowledging methodological plurality is not the same as abandoning scientific rigor, and that different types of evidence are needed to evaluate long-term safety and routine clinical implementation.[1][6]

Defenders also criticized the BMJ editorial for lumping vastly different practices under the umbrella term "complementary and alternative medicine." They note that systems like Ayurveda in India operate under statutory regulation, standardized university curricula, and institutional oversight, which is fundamentally different from the unregulated sale of commercial dietary supplements in Western markets.[1][4]

The debate also touches on deep historical and cultural sensitivities. Proponents of traditional medicine argue that dismissing centuries of indigenous knowledge solely because it hasn't been validated by Western trial structures borders on "epistemicide"—the erasure of non-Western knowledge systems. They point out that many modern pharmaceuticals, including the malaria drug artemisinin, originated from traditional botanical knowledge.[1][3]

Conversely, the BMJ authors counter that artemisinin became a global standard precisely because it was subjected to rigorous scientific evaluation, not out of deference to tradition. They maintain that the scientific method is not a colonial construct, but a universal tool designed to distinguish interventions that work from those that do not, regardless of their cultural origin.[1][5]

As the WHO Global Traditional Medicine Strategy rolls out over the next decade, member states will be left to navigate this tension. The WHO is currently building a Global Traditional Medicine Library to document both the claims of benefit and the evidence of harm. Ultimately, the challenge will be finding a regulatory middle ground that respects cultural heritage while uncompromisingly protecting patient safety.[2][4][6]